Clinical trial registry record

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 22, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05230537
Last registry update
September 22, 2026
Status
Active Not Recruiting
Phase
Phase 2
Sponsor
Novartis Pharmaceuticals
Enrollment
168
Countries
United States, China, Puerto Rico, United Kingdom
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
168
Population
ALL · 50 Years to 100 Years
Duration
2022-02-17 to 2026-09-30
Intervention
Iptacopan (LNP023); Placebo
Comparator
Placebo
Outcomes measured
Development of new incomplete retinal pigment epithelium & outer retinal atrophy or late age-related macular degenerati…; The incidence of ocular and non-ocular adverse events (AEs) — Baseline/Day 1 through Month 24; Change in Early Treatment Diabetic Retinopathy Study (ETDRS) (Standard Luminance) best corrected visual acuity (BCVA) s…; Change in ETDRS low luminance visual acuity (LLVA) scores in the early/intermediate AMD eye — Baseline/Day 1 through Mo…; Change in contrast sensitivity (CS) scores in the early/intermediate AMD eye — Baseline/Day 1 through Month 24; Change in Standard luminance manifold contrast vision meter contrast sensitivity (MCVM-CS) scores in the early/intermed…; Pharmacokinetics - concentrations of LNP023 related to trough samples — Baseline/Day 1 through Month 24; Change in low luminance manifold contrast vision meter (MCVM) contrast sensitivity scores in the early/intermediate AMD…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON